Amgen Inc. (AMGN): Price and Financial Metrics


Amgen Inc. (AMGN): $227.72

-1.18 (-0.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AMGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 459

in industry

AMGN POWR Grades


  • Quality is the dimension where AMGN ranks best; there it ranks ahead of 98.82% of US stocks.
  • AMGN's strongest trending metric is Growth; it's been moving up over the last 163 days.
  • AMGN's current lowest rank is in the Momentum metric (where it is better than 12.47% of US stocks).

AMGN Stock Summary

  • AMGN has a higher market value than 98.15% of US stocks; more precisely, its current market capitalization is $128,931,564,968.
  • The capital turnover (annual revenue relative to shareholder's equity) for AMGN is 3.14 -- better than 85.12% of US stocks.
  • AMGN's went public 36.08 years ago, making it older than 92.74% of listed US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Amgen Inc are SNY, IBM, MDT, BMY, and DE.
  • Visit AMGN's SEC page to see the company's official filings. To visit the company's web site, go to www.amgen.com.

AMGN Valuation Summary

  • In comparison to the median Healthcare stock, AMGN's price/sales ratio is 55.95% lower, now standing at 5.
  • Over the past 243 months, AMGN's price/earnings ratio has gone down 35.2.
  • Over the past 243 months, AMGN's price/sales ratio has gone down 13.1.

Below are key valuation metrics over time for AMGN.

Stock Date P/S P/B P/E EV/EBIT
AMGN 2021-08-31 5.0 15.5 22.3 20.1
AMGN 2021-08-30 5.0 15.4 22.1 20.0
AMGN 2021-08-27 5.0 15.3 22.0 19.9
AMGN 2021-08-26 4.9 15.2 21.9 19.8
AMGN 2021-08-25 4.9 15.3 21.9 19.8
AMGN 2021-08-24 5.0 15.4 22.2 20.0

AMGN Growth Metrics

    The 5 year cash and equivalents growth rate now stands at 165.44%.
  • Its 5 year net cashflow from operations growth rate is now at -2.32%.
  • Its 5 year net income to common stockholders growth rate is now at 6.36%.
Over the past 15 months, AMGN's revenue has gone up $1,466,000,000.

The table below shows AMGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 25,767 8,606 5,609
2021-06-30 25,484 9,556 5,746
2021-03-31 25,164 10,467 7,085
2020-12-31 25,424 10,497 7,264
2020-09-30 24,987 10,858 7,352
2020-06-30 24,301 10,867 7,299

AMGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AMGN has a Quality Grade of A, ranking ahead of 98.04% of graded US stocks.
  • AMGN's asset turnover comes in at 0.412 -- ranking 113th of 682 Pharmaceutical Products stocks.
  • UTHR, NBY, and AERI are the stocks whose asset turnover ratios are most correlated with AMGN.

The table below shows AMGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.412 0.754 0.169
2021-06-30 0.408 0.753 0.169
2021-03-31 0.395 0.756 0.196
2020-12-31 0.400 0.758 0.206
2020-09-30 0.398 0.767 0.220
2020-06-30 0.395 0.782 0.225

AMGN Price Target

For more insight on analysts targets of AMGN, see our AMGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $250.00 Average Broker Recommendation 1.78 (Moderate Buy)

AMGN Stock Price Chart Interactive Chart >

Price chart for AMGN

AMGN Price/Volume Stats

Current price $227.72 52-week high $276.69
Prev. close $228.90 52-week low $198.64
Day low $227.31 Volume 3,535,000
Day high $231.46 Avg. volume 2,610,971
50-day MA $217.23 Dividend yield 3.09%
200-day MA $228.53 Market Cap 128.27B

Amgen Inc. (AMGN) Company Bio


Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980. Amgen's Thousand Oaks staff in 2017 numbered 5,125 (7.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura County. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology. (Source:Wikipedia)  


AMGN Latest News Stream


Event/Time News Detail
Loading, please wait...

AMGN Latest Social Stream


Loading social stream, please wait...

View Full AMGN Social Stream

Latest AMGN News From Around the Web

Below are the latest news stories about Amgen Inc that investors may wish to consider to help them evaluate AMGN as an investment opportunity.

Japan Approves Amgen’s LUMAKRAS

or recurrent non-small cell lung cancer (NSCLC) that has progressed post systemic anticancer therapy.  Notably, in March 2021, LUMAKRAS was granted Orphan Drug Designation by the Japan Ministry of Health, Labour, and Welfare (MHLW).  Supporting Data  Amgen said that the regulator’s approval followed positive data from the Phase 2 CodeBreaK 100 clinical trial in NSCLC. LUMAKRAS 960 mg, which was administered orally once-daily, showed an objective response rate (ORR) of 37% in 123 participants.

Priti Ramgarhia on TipRanks | January 21, 2022

Amgen''s (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer | Investing.com

Stocks Analysis by Zacks Investment Research covering: Amgen Inc, Dynavax Technologies Corporation, Mirati Ther, AnaptysBio Inc. Read Zacks Investment Research''s latest article on Investing.com

Investing.com | January 21, 2022

3 Healthcare Stocks With High Dividends

So far 2022 has been brutal for growth stocks. A good place to hide might be the healthcare sector. It's a great defensive play, as healthcare is as basic as food. And these stocks all pay a nice dividend.

Yahoo | January 21, 2022

Beacon Financial Advisory LLC Buys McDonald's Corp, First Trust NASDAQ Rising Dividend ...

Investment company Beacon Financial Advisory LLC (Current Portfolio) buys McDonald's Corp, First Trust NASDAQ Rising Dividend Achievers ETF, Nucor Corp, PIMCO Intermediate Municipal Bond Active Exchange-, iShares 0-5 Year TIPS Bond ETF, sells Tesla Inc, Paychex Inc, iShares MBS ETF, iShares Fallen Angels USD Bond ETF, iShares 1-3 Year Credit Bond ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Beacon Financial Advisory LLC.

Yahoo | January 21, 2022

Amgen's (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer

Amgen's (AMGN) KRAS inhibitor, Lumakras, gets approval in Japan for the treatment of KRAS G12C-mutated positive advanced/recurrent non-small-cell lung cancer.

Yahoo | January 21, 2022

Read More 'AMGN' Stories Here

AMGN Price Returns

1-mo 1.76%
3-mo 9.75%
6-mo -5.58%
1-year -7.39%
3-year 23.33%
5-year 72.25%
YTD 1.22%
2021 0.87%
2020 -1.99%
2019 27.60%
2018 15.23%
2017 22.27%

AMGN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AMGN Dividend History

Continue Researching AMGN

Want to see what other sources are saying about Amgen Inc's financials and stock price? Try the links below:

Amgen Inc (AMGN) Stock Price | Nasdaq
Amgen Inc (AMGN) Stock Quote, History and News - Yahoo Finance
Amgen Inc (AMGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.732 seconds.